Overview

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2020-07-22
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Timolol
Criteria
Inclusion Criteria:

- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
require IOP-lowering treatment.

Exclusion Criteria:

- Previous enrollment in another Allergan Bimatoprost SR Study

- Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
6 months in the study eye

- Anticipated need for laser eye surgery within the first 52 weeks of the study duration

- History of glaucoma surgery